Opelconazole

Summary

Opelconazole (CHEMBL4650362) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including pulmonary aspergilloma and aspergillosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 682.7 Da · C38H37F3N6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650362
Name	Opelconazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	121383526
Molecular formula	C38H37F3N6O3
Molecular weight	682.7
InChIKey	OSAMZQJKSCAOHA-CWRQMEKBSA-N

SMILES: CC1=C(C=CC(=C1)N2CCN(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)F)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F

IUPAC name: 4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]-3-methylphenyl]piperazin-1-yl]-N-(4-fluorophenyl)benzamide

Also known as: Opelconazole, Opelconazole(inn), PC-945, Pc945, PC945, OPELCONAZOLE

Patent coverage: 17 distinct patent families (56 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 51 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pulmonary aspergilloma	2	MONDO:0000266	EFO:1001834
aspergillosis	1	MONDO:0005657	EFO:0007157

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05238116	PHASE3	TERMINATED	Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
NCT03745196	PHASE2	TERMINATED	The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
NCT03870841	PHASE2	TERMINATED	The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
NCT03905447	PHASE2	TERMINATED	The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
NCT05037851	PHASE2	COMPLETED	An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).